AstraZeneca (LON:AZN) Shares Break Below 200 Day Moving Average – What’s Next?

AstraZeneca PLC (LON:AZN – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of £134.38 and traded as low as £132.74. AstraZeneca shares last traded at £133.09, with a volume of 1,706,220 shares traded.

Analysts Set New Price Targets

AZN has been the subject of several recent research reports. Deutsche Bank lifted their price target on AstraZeneca from £117 to £120 and gave the company a “hold” rating in a research report on Friday, November 6th. Berenberg Bank reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a report on Wednesday, October 7th. Jefferies Financial Group reissued a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday. Citigroup boosted their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Finally, Royal Bank Of Canada started coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating and a £145 target price on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average target price of £155.50.

Read Our Latest Stock Analysis on AZN

AstraZeneca Price Performance

The company has a current ratio of 1.01, a quick ratio of 0.59 and a debt-to-equity ratio of 66.10. The company has a market capitalization of £206.41 billion, a P/E ratio of 18.85, a P/E/G ratio of 0.86 and a beta of 0.21. The business’s fifty day moving average price is £128.21 and its 200-day moving average price is £134.38.

Insider Buying and Selling

In other news, insider Michel Demare acquired 2,500 shares of the stock in a transaction dated Monday, September 14th. The stock was purchased at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is owned by corporate insiders.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Read More

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.